Palmitoylethanolamide (PEA) Palmidrol CAS 544-31-0 Amino Acid

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly
• State: Solid
• Purity: >99%
• Model NO.: TGYBIO
• Product Name: Palmitoylethanolamide
• Appearance: White Powder
• Test Methods: HPLC
• Shelf Life: 2 Years
• Shipping Methods: DHL, FedEx, TNT and EMS
• MOQ: 100g
• Grade: Pharmaceutical Grade
• Transport Package: Foil Bag, Box, Drum
• Specification: 99%min
• Trademark: TGY
• Origin: China
• Production Capacity: 100kg/Month

Product Description

Product Name	Palmitoylethanolamide
Specification	99%
Molecular Formula	C18H37NO2
Molecular Weight	299.49

Palmitoylethanolamide(pea) Powder is an endogenous fatty acid amide, belonging to the class of nuclear factor agonists.

PEA has been demonstrated to bind to a receptor in the cell-nucleus (a nuclear receptor) and exerts a great variety of biological functions related to chronic pain and inflammation. The main target is thought to be the peroxisome proliferator-activated receptor alpha (PPAR-α).

 

PEA has been explored in humans; spanning various clinical trials in a variety of pain states, for inflammatory and pain syndromes. Its positive influence in atopic eczema for instance seems to originate from PPAR alpha activation. PEA is available for human use as a dietary supplement.
 
In a 2012 review, all clinical trials to date were summarized. In a 2015 analysis of a double blind placebo controlled study of PEA in sciatic pain, the Numbers Needed to Treat was 1.5. Its positive influence in chronic pain, and inflammatory states such as atopic eczema, seems to originate mainly from PPAR alpha activation. Since 2012 a number of new trials have been published, among which studies in glaucoma. PEA also seems to be one of the factors responsible for the decrease in pain sensitivity during and after sport, comparable to the endogenous opiates (endorphines).